Gut Associated Metabolites Enhance PD-L1 Blockade Efficacy in Prostate Cancer.

ABSTRACT:

Background

The gut microbiome has emerged as a critical modulator of cancer immunotherapy response. However, the mechanisms by which gut-associated metabolites influence checkpoint blockade efficacy in prostate cancer (PC) remain not fully explored. The study aimed to explore how gut metabolites regulate death-ligand 1 (PD-L1) blockade via exosomes and boost immune checkpoint inhibitors (ICIs) in PC.

Methods

We recruited 70 PC patients to set up into five subgroups. The integrated multi-omics analysis was performed. In parallel, we validated the function of gut microbiome-associated metabolites on PD-L1 production and immunotherapy treatment efficacy in PC cell lines and transgenic adenocarcinoma of the mouse prostate (TRAMP) models.

Results

We identified two metaboli

SUBMITTER: Liu K 

PROVIDER: S-EPMC12848745 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature